For research use only. Not for therapeutic Use.
Orally active PI3K/mTOR tyrosine kinase inhibitor; matching the profile of XL 765.
Note: XL 765 has an updated CAS registry number [934493-76-2].
| Catalog Number | I047554 |
| CAS Number | 934529-30-3 |
| Molecular Formula | C31H29N5O6S |
| Purity | ≥95% |
| IUPAC Name | N-[3-[[3-(3,5-dimethoxyanilino)quinoxalin-2-yl]sulfamoyl]phenyl]-3-methoxy-4-methylbenzamide |
| InChI | InChI=1S/C31H29N5O6S/c1-19-12-13-20(14-28(19)42-4)31(37)33-21-8-7-9-25(17-21)43(38,39)36-30-29(34-26-10-5-6-11-27(26)35-30)32-22-15-23(40-2)18-24(16-22)41-3/h5-18H,1-4H3,(H,32,34)(H,33,37)(H,35,36) |
| SMILES | CC1=C(C=C(C=C1)C(=O)NC2=CC(=CC=C2)S(=O)(=O)NC3=NC4=CC=CC=C4N=C3NC5=CC(=CC(=C5)OC)OC)OC |
| Reference | C Garcia-Echeverria and WR Sellers. Drug discovery approaches targeting the PI3K/Akt pathway in cancer. Oncogene. 2008, 27(41), 5511-5526.
W Gordon et al. Inhibitors of phosphatidylinositol 3-kinases: The next wave of anti-cancer drugs? Chem. New Zealand. 2009, 9-11.
SM Maria, P Furet and F Stauffer. Discovery of novel anticancer therapeutics targeting the PI3K/Akt/mTOR pathway. Future Med. Chem. 2009, 1(1), 137-155.
E Vilar et al. Pushing the envelope in the mTOR pathway: the second generation of inhibitors. Mol. Cancer Ther. 2011, 10(3), 395-403. |
